Drug intelligence / Profile preview

PreMenora

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PreMenora is a multi-ingredient dietary supplement developed by PreEmptive Meds (PMeds) as part of its "Pre-Disease" product line. It is specifically formulated to manage and alleviate symptoms associated with menopause and perimenopause, such as hot flashes, night sweats, and mood swings. The formulation combines essential vitamins, including Vitamin D3 and Vitamin B12, with a proprietary blend of botanical extracts designed to support hormonal balance and overall wellness during the menopausal transition. PreMenora is marketed directly to consumers as a clinically-graded nutraceutical intervention for women experiencing hormonal shifts.

Brand names: PreMenora

Targets

VDR (Vitamin D receptor)ER (Estrogen receptor)

Beyond the preview

Go deeper on PreMenora.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PreMenora.

Explore the full profile